Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience
- Author(s)
- Euncheol Choi; Jin Hee Kim; Ok Bae Kim; Mi Young Kim; Young Ki Oh; Sung Gyu Baek
- Keimyung Author(s)
- Kim, Jin Hee; Kim, Ok Bae; Oh, Young Kee; Baek, Seong Kyu
- Department
- Dept. of Radiation Oncology (방사선종양학)
Dept. of Surgery (외과학)
- Journal Title
- Radiation Oncology Journal
- Issued Date
- 2016
- Volume
- 34
- Issue
- 2
- Keyword
- Rectum; Rectal neoplasms; Chemoradiotherapy; Stage; Interval
- Abstract
- Purpose: To identify possible predictors of pathologic complete response (pCR) of rectal cancer after preoperative concurrent
chemoradiotherapy (CCRT).
Materials and Methods: We conducted a retrospective review of 53 patients with rectal cancer who underwent preoperative
CCRT followed by radical surgery at a single center between January 2007 and December 2012. The median radiotherapy dose to
the pelvis was 54.0 Gy (range, 45.0 to 63.0 Gy). Five-fluorouracil-based chemotherapy was administered via continuous infusion
with leucovorin.
Results: The pCR rate was 20.8%. The downstaging rate was 66%. In univariate analyses, poor and undifferentiated tumors (p =
0.020) and an interval of ≥7 weeks from finishing CCRT to surgery (p = 0.040) were significantly associated with pCR, while female
gender (p = 0.070), initial carcinoembryonic antigen concentration of <5.0 ng/dL (p = 0.100), and clinical stage T2 (p = 0.100) were
marginally significant factors. In multivariate analysis, an interval of ≥7 weeks from finishing CCRT to surgery (odds ratio, 0.139;
95% confidence interval, 0.022 to 0.877; p = 0.036) was significantly associated with pCR, while stage T2 (odds ratio, 5.363; 95%
confidence interval, 0.963 to 29.877; p = 0.055) was a marginally significant risk factor.
Conclusion: We suggest that the interval from finishing CCRT to surgery is a predictor of pCR after preoperative CCRT in patients
with rectal cancer. Stage T2 cancer may also be an important predictive factor. We hope to perform a robust study by collecting
data during treatment to obtain more advanced results.
- 공개 및 라이선스
-
- 파일 목록
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.